Skip to main content
ASTRO 2024 Main banner
Icon Legend
Presentation Icons
Event Add-on
Event Add-on
In Person Only
In Person Only
Off-site Event
Off-site Event
Location: Marriott Marquis
Location: Marriott Marquis
Back

Special Session
Session Type: Poster Q & A

PQA 01 - PQA 01 Lung Cancer/Thoracic Malignancies and Diversity, Equity and Inclusion in Healthcare Poster Q&A

Sunday, September 29, 2024
2:45 PM – 4:15 PM ET
Location: Hall C

In Person Only

    This event is in-person only and won't be livestreamed or available onDemand.

    Presentations:

    • 2:45 PM – 4:15 PM ET
      Local Control by Motion Management Strategy of Thoracic Tumors: Secondary Analysis of the iSABR Trial

      Presenter: Joseph Abi Jaoude, MD – Stanford University

    • 2:45 PM – 4:15 PM ET
      Worldwide Utilization of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Are We All in Sync?

      Presenter: Salem Alfaifi, MD, FRCPC – Cleveland Clinic

    • 2:45 PM – 4:15 PM ET
      Radiotherapy Resources in Central Asia: An International Atomic Energy Agency Update

      Presenter: Sondos AlKhatib, MD – Henry Ford Cancer Institute

    • 2:45 PM – 4:15 PM ET
      Understanding Equity, Diversity and Inclusion within Canadian Radiation Oncology: Experiences of Residents and Fellows

      Presenter: Jennifer Croke, MD, MHPE – Princess Margaret Cancer Centre

    • 2:45 PM – 4:15 PM ET
      Patterns and Predictors of Pneumonitis after Chemoradiation Followed by Durvalumab

      Presenter: Lee Wilk – Sheba Medical Center

    • 2:45 PM – 4:15 PM ET
      Recent Industry Payment Trends across Radiation Oncology Residency Program Leadership

      Presenter: Rojine Ariani, MD, MS – UCLA David Geffen School of Medicine/UCLA Medical Center

    • 2:45 PM – 4:15 PM ET
      The Impact of Rural Residence on Patient-Reported Toxicities and Outcomes of Prostate Cancer

      Presenter: Mariam Atobiloye, BS – University of Utah School of Medicine

    • 2:45 PM – 4:15 PM ET
      Racial Disparities in Survival and Local Recurrence Among People of Color with Anal Cancer

      Presenter: Nicholas Bader, MD – Emory University School of Medicine

    • 2:45 PM – 4:15 PM ET
      Project PARENT: An Open Access Family Leave Database for US Radiation Oncology and Medical Physics Residency Programs

      Presenter: Claire Baniel, MD – Stanford University

    • 2:45 PM – 4:15 PM ET
      Efficacy of Postoperative Radiotherapy for Patients with 9th Stage N2 Descriptors in Completely Resected Non-Small Cell Lung Cancer: A Real-World Study

      Presenter: Yongxing Bao, MD – National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC

    • 2:45 PM – 4:15 PM ET
      Should All Medically Inoperable Patients with Early-Stage NSCLC Need SBRT Treatment?

      Presenter: Tithi Biswas, MD, MBBS – University of Florida

    • 2:45 PM – 4:15 PM ET
      A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer (NCI 10512)

      Presenter: Tithi Biswas, MD, MBBS – University of Florida

    • 2:45 PM – 4:15 PM ET
      5-Year Single-Institution Experience of Single-Fraction SABR for Non-Small Cell Lung Cancer

      Presenter: Myriam Bouchard, MD – CHUS

    • 2:45 PM – 4:15 PM ET
      Predictive Value of Esophageal Circumferential Dose-Length Parameters for Dysphagia in Patients Receiving Thoracic Radiotherapy

      Presenter: Andrea Brown, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

    • 2:45 PM – 4:15 PM ET
      Association of Private vs. Public Postsecondary Education and Matriculation into Highly Ranked Radiation Oncology (RO) Residency Programs

      Presenter: Ria Brown, MD, BS – Wellstar Kennestone Hospital

    • 2:45 PM – 4:15 PM ET
      Outcomes and Toxicity in Patients Treated with Stereotactic Body Radiation Therapy for Ultracentral Lung Tumors at a Single Institution

      Presenter: David Buchberger, MD, MSc – Cleveland Clinic Foundation

    • 2:45 PM – 4:15 PM ET
      Dose to the Cardiac Substructures/Great Vessels and Survival in Patients Treated with Definitive Stereotactic Body Radiation Therapy for Lung Tumors - A Pilot Study

      Presenter: David Buchberger, MD, MSc – Cleveland Clinic Foundation

    • 2:45 PM – 4:15 PM ET
      Predictors of Atrial Fibrillation after Thoracic Radiotherapy

      Presenter: Santino Butler, MD – Stanford University School of Medicine

    • 2:45 PM – 4:15 PM ET
      Neoadjuvant Camrelizumab Combined with Chemotherapy for Resectable Stage IIIA-IIIB Non-Small Cell Lung Cancer: Single Arm Phase II Study

      Presenter: Guoxin Cai, MD, PhD – Shandong Cancer Hospital and Institute

    • 2:45 PM – 4:15 PM ET
      Role of Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer Patients with Baseline Brain Metastases: A Retrospective Analysis Using IPTW-Adjusted Models

      Presenter: Zhang Chaonan, MD

    • 2:45 PM – 4:15 PM ET
      Influence of Ethnicity and Birthplace on Breast Cancer Clinical Features, Treatment and Survival among Texas Women

      Presenter: Ashley Chavana, BS – Baylor College of Medicine

    • 2:45 PM – 4:15 PM ET
      Treatment-Associated Lymphopenia from Hypofractionated vs. Conventional Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer

      Presenter: Kevin Chen, MD, MSCI – Washington University in St. Louis

    • 2:45 PM – 4:15 PM ET
      Establishing Radiotherapy Quality Indicators for Lung Cancer: A Modified Delphi Study

      Presenter: Kim-Lin Chiew, MBBS – Princess Alexandra Hospital

    • 2:45 PM – 4:15 PM ET
      Predicting Thoracic Toxicity with Large Vision Foundation Model Using Pretreatment Data

      Presenter: Chloe Choi, MS – Memorial Sloan Kettering Cancer Center

    • 2:45 PM – 4:15 PM ET
      Income and Regional Inequities in Rectal Spacer Utilization among Prostate Cancer Patients

      Presenter: Sean Collins, MD, PhD – Tampa General Hospital

    • 2:45 PM – 4:15 PM ET
      Analysis of Sex Inequities in Medicare and Industry Payments in Radiation Oncology

      Presenter: Patrick Courtney, MD, MAS – UCLA David Geffen School of Medicine/UCLA Medical Center

    • 2:45 PM – 4:15 PM ET
      Role of Whole-Heart Cardiac Dose (WH-CD) on OS in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Receiving Post-Operative Radiotherapy (PORT)

      Presenter: Ruben Cruz-Chamorro, MD – Moffitt Cancer Center

    • 2:45 PM – 4:15 PM ET
      Clinical Outcomes of Early-Stage NSCLC Treated with Definitive SBRT by KRAS and EGFR Status and PD-L1 Expression

      Presenter: Erik Davies, MD – Cleveland Clinic Taussig Cancer Center

    • 2:45 PM – 4:15 PM ET
      Role of Whole-Heart Dose on Overall Survival (OS) in Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Patients (Pts) Treated with Concurrent Definitive Chemoradiotherapy (CDCRT)

      Presenter: Thomas Dilling, MD, MS, FASTRO – Moffitt Cancer Center

    • 2:45 PM – 4:15 PM ET
      Role of Cardiac Sub-Structure (CSS) Dose on Overall Survival (OS) in Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Patients (Pts) Treated with Concurrent Definitive Chemoradiotherapy (CDCRT)

      Presenter: Thomas Dilling, MD, MS, FASTRO – Moffitt Cancer Center

    • 2:45 PM – 4:15 PM ET
      Development and Implementation of a Diversity, Equity and Inclusion Task Force in a Radiation Oncology Department at an NCI-Designated Comprehensive Cancer Center

      Presenter: Jason Domogauer, MD, PhD – NYU Langone Laura and Isaac Perlmutter Cancer Center

    • 2:45 PM – 4:15 PM ET
      Uptake of Attendee Pronoun Selection at Time of Registration for the 65th ASTRO Annual Meeting

      Presenter: Jason Domogauer, MD, PhD – NYU Langone Laura and Isaac Perlmutter Cancer Center

    • 2:45 PM – 4:15 PM ET
      Online Adaptive Radiotherapy for Limited-Stage Small Cell Lung Cancer: A Prospective, Single-Armed, Phase II Trial

      Presenter: Baiqiang Dong, MD, PhD – Sun Yat-Sen University Cancer Center

    • 2:45 PM – 4:15 PM ET
      Postoperative Pleural Fluid Cell-Free DNA Captures Locoregional MRD That Stratifies Risk for Lung Cancer Relapse after Surgery

      Presenter: Noah Earland, PhD, BS – Washington University in St. Louis School of Medicine

    • 2:45 PM – 4:15 PM ET
      Prospective Evaluation of Non-Small Cell Lung Cancer Radiation Therapy Treatment Interruptions in a Large Statewide Quality Collaborative

      Presenter: Ameer Elaimy, MD, PhD, BS – University of Michigan

    • 2:45 PM – 4:15 PM ET
      Inducing Abscopal Response by Local Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor as Monotherapy in Patients with Pretreated Advanced Thymic Epithelial Tumors: A Retrospective Anal

      Presenter: Min Fan, MD, PhD

    • 2:45 PM – 4:15 PM ET
      Impact of Radiation Therapy on Long-Term Survival in Patients with KRAS-Mutant Stage IV NSCLC Treated with Immune Checkpoint Inhibitors

      Presenter: Sayeh Fattahi, MD – Harvard Radiation Oncology Program

    • 2:45 PM – 4:15 PM ET
      Clinical Efficacy of Postoperative Radiotherapy for High-Risk Locoregional Recurrence in Patients with Completely Resected Pathologic Stage IIIA(N2) Non-Small Cell Lung Cancer: A Propensity Score-Matc

      Presenter: Wen Feng, MD – Shanghai Chest Hospital Shanghai Jiao Tong University

    • 2:45 PM – 4:15 PM ET
      A 3D CNN Model Using Deep Learning Based on Chest CT for Predicting Disease-Free Survival of Patients with Early Stage Lung Cancer Receiving Surgery and SBRT

      Presenter: Yuanyuan Fu, MD

    • 2:45 PM – 4:15 PM ET
      Benefit of Consolidative Thoracic Radiotherapy Following First-Line Chemoimmunotherapy in Metastatic NSCLC: Based on PD-L1 Expression

      Presenter: Aiqin Gao, PhD – Shandong Cancer Hospital Affiliated to Shandong First Medical University

    • 2:45 PM – 4:15 PM ET
      Correlation between irAEs and Efficacy of Consolidative PD-(L)1 Inhibitors Following Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer

      Presenter: Aiqin Gao, PhD – Shandong Cancer Hospital Affiliated to Shandong First Medical University

    • 2:45 PM – 4:15 PM ET
      Immunomodulatory Effects of Lung SBRT in the Primary and Metastatic Setting: Results from the LAPIS Studies

      Presenter: Eleni Gkika, MBA

    • 2:45 PM – 4:15 PM ET
      Geographical Disparities in Access to Radiotherapy in Brazil: An Observational Study

      Presenter: Andre Gouveia, MD – McMaster University

    • 2:45 PM – 4:15 PM ET
      Association of Private Schooling with Matching at Highly Ranked Radiation Oncology (RO) Residency Programs: An Analysis of the Texas Star Dataset

      Presenter: Elaine Cha, MD – MD Anderson Cancer Center

    • 2:45 PM – 4:15 PM ET
      Pretreatment Maximum Standard Uptake Value (SUV max) on Positron Emission Tomography (PET) and the Risk of Distant Failure for Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) Receiving Stereo

      Presenter: Nilanjan Haldar, MD, BS – Thomas Jefferson University

    • 2:45 PM – 4:15 PM ET
      Rates of Attrition in Black Patients with Prostate Cancer Enrolled in Randomized Controlled Trials: A Pooled Secondary Analysis of RTOG 9601, 9902, 0126, and 0415

      Presenter: Muhammad Hamza, MD, BS – University of Maryland Radiation Oncology

    • 2:45 PM – 4:15 PM ET
      A Single-Arm Pilot Study of Combined SBRT and Electric Ablation for Lung Tumors

      Presenter: Jeremy Harris, MD, MPhil – University of California Irvine

    • 2:45 PM – 4:15 PM ET
      Impact of Radiation Dose to the Immune Cells on Lymphopenia for Stage IV Non-Small Cell Lung Cancer Receiving Immunotherapy and Radiotherapy

      Presenter: Jun yi He, BS

    • 2:45 PM – 4:15 PM ET
      Effect of Distance and Sociodemographic Variables on Radiotherapy Recommendation, Initiation and Completion

      Presenter: Jacob Hogan, BS – Washington University in St. Louis School of Medicine

    • 2:45 PM – 4:15 PM ET
      Lactic Acidosis as a Potential Mechanism of Unexpected Cardiac Toxicity following Chemoradiation Therapy for Non-Small Cell Lung Cancer

      Presenter: Kristian Holgersson, BS – Loma Linda University School of Medicine

    • 2:45 PM – 4:15 PM ET
      Integrating CT Images and Radiotherapy Dose Distribution Maps to Predict the Progression-Free Survival in Locally Advanced Non-Small Cell Lung Cancer Patients

      Presenter: Runping Hou, PhD – Shanghai Chest Hospital Shanghai Jiao Tong University

    • 2:45 PM – 4:15 PM ET
      Overestimation of Contralateral Hilar Lymph Node Metastasis in Non-Metastatic Non-Small Cell Lung Cancer and Its Predictive Model: HAM

      Presenter: Zan Hou, MD – Sun Yat-Sen University Cancer Center

    • 2:45 PM – 4:15 PM ET
      Assessing the Correlation between Travel Burden and Socioeconomic Status in Radiotherapy Access across Taiwanese Towns

      Presenter: Wen-Han Hsieh, MD, MS – Taipei Veterans General Hospital

    • 2:45 PM – 4:15 PM ET
      Examining Potential Barriers to Obtaining Decipher Scores in Prostate Adenocarcinoma Considered for Radiation

      Presenter: Audree Hsu, MD – Providence St. Vincent Medical Center

    • 2:45 PM – 4:15 PM ET
      SP1-Activated LINC00167 and Angiogenesis in Human NSCLC Cells

      Presenter: Hao Huang, PhD

    • 2:45 PM – 4:15 PM ET
      Digital Spatial Profiling of the Tumor Microenvironment in Patients with Advanced Non-Small Cell Lung Cancer Reveals Biomarkers of Response to Anti-PD1 Antibody

      Presenter: Xinyi Huang, MD

    • 2:45 PM – 4:15 PM ET
      Feasibility Study of Dose De-Escalation in Postoperative Intensity-Modulated Radiation Therapy (IMRT) for Stage II-III Thymoma

      Presenter: Youn Ji Hur, MD

    • 2:45 PM – 4:15 PM ET
      Accelerated Hypofractionated Radiotherapy for the Definitive Management of Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review

      Presenter: Badr Id Said, MD, MS – MD Anderson Cancer Center

    • 2:45 PM – 4:15 PM ET
      Unplanned Hospitalizations and Lymphopenia after Proton Beam Therapy (PBT) vs. Intensity-Modulated Radiation Therapy (IMRT) in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC): An Analysis of 74

      Presenter: Michelle Iocolano, MD, MA – University of Pennsylvania

    • 2:45 PM – 4:15 PM ET
      Hypofractionation Improving Loco-Regional Control for Sequential Chemoradiotherapy in Non-Small Cell Lung Cancer. A Multicenter Long Term Experience.

      Presenter: Alexandre Jacinto, MD, PhD – Hospital de Cancer de Barretos

    • 2:45 PM – 4:15 PM ET
      Outcomes of Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic or Oligoprogressive Lung Metastases from Renal Cell Cancer (RCC)

      Presenter: Xuemei Ji, MD – Yale University

    • 2:45 PM – 4:15 PM ET
      SPICE Planning for Volumetric Modulated Arc Therapy SBRT in Early-Stage NSCLC: Some Like it Hot!

      Presenter: Bryan Johnson, MD, MBA – Mayo Clinic Florida

    • 2:45 PM – 4:15 PM ET
      Characterizing Post-Treatment Cardiac and Pulmonary Hospitalizations in Locally Advanced Lung Cancer: A Statewide Quality Consortium Analysis

      Presenter: Shruti Jolly, MD, MBA – University of Michigan

    • 2:45 PM – 4:15 PM ET
      Circulating miRNA Profiling Distinguishes Radiation-Induced Fibrosis from Locoregional Recurrence in Patients Who Received Radiotherapy for Lung Cancer

      Presenter: Jesus Juarez Casillas, MD, MS – UCLA

    • 2:45 PM – 4:15 PM ET
      Demographic Attributes among ASTRO Fellow Awardees between 2006 and 2023

      Presenter: Sophia Kamran, MD – Massachusetts General Hospital

    • 2:45 PM – 4:15 PM ET
      Incidence and Outcome of Brain Metastasis in NSCLC with KRAS Mutation. An Observational Study

      Presenter: Muneeb Uddin Karim, MBBS, FCPS – McGill University

    • 2:45 PM – 4:15 PM ET
      Safety and Efficacy of Lung SBRT Alone or in Combination with Concurrent Systemic Therapies

      Presenter: Silpa Karipineni, BS – University of Southern California Keck School of Medicine

    • 2:45 PM – 4:15 PM ET
      What Can 5,045 Peripheral Lymphocyte Count Measurements in 255 Patients Tell Us About Temporal Dynamics and Survival in Non-Small Cell Lung Cancer?

      Presenter: Vaiva Kaveckyte, PhD – Copenhagen University Hospital Rigshospitalet

    • 2:45 PM – 4:15 PM ET
      Radiation Oncologists in Canada: A Comprehensive Survey of Gender Identity, Sexual Orientation, Disability, Race, Ethnicity, Religion and Workplace Harassment and Discrimination Experience

      Presenter: Amanda Khan, MD, PhD – Tom Baker Cancer Centre / University of Calgary

    • 2:45 PM – 4:15 PM ET
      Risk of Clinically Significant Cardiovascular Disease Associated with Postoperative Radiotherapy in Non-Small Cell Lung Cancer Patients Receiving Surgical Resection Followed By Adjuvant Chemotherapy:

      Presenter: Byoung Hyuck Kim, MD, PhD – Seoul National University College of Medicine

    • 2:45 PM – 4:15 PM ET
      Risk Analysis of Radiation Pneumonitis after Stereotactic Body Radiotherapy for Central Non-Small Cell Lung Cancer

      Presenter: Nozomi Kita, MD, PhD – Nagoya City University Graduate School of Medical Sciences

    • 2:45 PM – 4:15 PM ET
      Income Inequality in Patients (Pts) with Locally Advanced (LA) Non-Small Cell Lung Cancer (NSCLC) Receiving Proton Beam Therapy

      Presenter: Andre Konski, MD, MBA, MS, FASTRO – University of Pennsylvania

    • 2:45 PM – 4:15 PM ET
      Systematic analysis of cancer-testis specific genes identifies potential targets for lung adenocarcinoma radiosensitization

      Presenter: Tangmin Lai, MS

    • 2:45 PM – 4:15 PM ET
      Transportation Insecurity among Patients with Cancer Undergoing Radiation Therapy

      Presenter: Kaitlyn Lapen, MD – Memorial Sloan Kettering Cancer Center

    • 2:45 PM – 4:15 PM ET
      Deep Learning Based Estimation of Facial Age for Prognostication in Patients with Early-Stage Non-Small Cell Lung Cancer Undergoing Definitive Stereotactic Body Radiotherapy

      Presenter: Grace Lee, MD – Harvard Radiation Oncology Program

    • 2:45 PM – 4:15 PM ET
      Dysfunction of CD8+ T Cells around Tumor Cells and Occult Lymph Node Metastasis in NSCLC Patients

      Presenter: Chaozhuo Li, MS

    • 2:45 PM – 4:15 PM ET
      Treatment Toxicity and Outcomes Following Definitive Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancers and Pre-Existing Interstitial Lung Disease - A Systematic Review

      Presenter: George Li, MD – University of Toronto

    • 2:45 PM – 4:15 PM ET
      Irradiated Tumor Cell-Released Microparticles and the Therapeutic Efficacy of PD-1 Inhibitors by Promoting M1-TAMs Polarization in NSCLC Brain Metastases

      Presenter: Ji Li, MD

    • 2:45 PM – 4:15 PM ET
      Hypofraction Radiotherapy (4Gy/f) for Limited-Stage Small Cell Lung Cancer: A Phase I/II Trial

      Presenter: Xiaoyang Li, MD, PhD – Shanghai Chest Hospital, Shanghai JiaoTong University

    • 2:45 PM – 4:15 PM ET
      Mouse Mesenchymal Stem Cell-Derived Exosomal miR-466f-3p Reverses EMT Process through Inhibiting AKT/GSK3ß Pathway via c-MET in Radiation-Induced Lung Injury

      Presenter: Yi Li, MD – The 920th Hospital of The Joint Logistic Support Forth

    • 2:45 PM – 4:15 PM ET
      Beta-Adrenergic Receptor Blockers and Survival in Patients with Advanced Non-Small Cell Lung Cancer Combined with Hypertension Undergoing Radiotherapy

      Presenter: Xinyi Liang, MS

    • 2:45 PM – 4:15 PM ET
      Reduced Frequency and Severity of Radiation Esophagitis without Marginal Failure Risk By Contralateral Esophagus Sparing IMRT in Stage III Non-Small Cell Lung Cancer Patients Undergoing Definitive Con

      Presenter: Haesol Lim, MD – Samsung Medical Center

    • 2:45 PM – 4:15 PM ET
      Histology-Driven Hypofractionated Radiotherapy Schemes for Early-Stage Lung Adenocarcinoma and Squamous Cell Carcinoma

      Presenter: Michael Farris, MD – Wake Forest University Medical Center

    • 2:45 PM – 4:15 PM ET
      Induction or Consolidation Immunotherapy in Unresectable Stage III NSCLC Treated with Definitive Radiotherapy: A Retrospective Study

      Presenter: Xia Gan, MBBS – Hunan Cancer Hospital

    • 2:45 PM – 4:15 PM ET
      Negative Predictors for Surgery Following Induction Chemo-Immunotherapy in Patients with Stage IB-III NSCLC between 2017-2021

      Presenter: Jason Liu, MD – City of Hope South Pasadena

    • 2:45 PM – 4:15 PM ET
      [18F]AlF-NOTA-QHY-04 PET/CT may Predict Short-Term Outcome for Patients with Limited-Stage Small Cell Lung Cancer Treated by Concurrent Chemoradiotherapy

      Presenter: Jingru Liu, MD

    • 2:45 PM – 4:15 PM ET
      Characterizing Metabolomic Signatures for Early Metastasis in Non-Small Cell Lung Cancer Patients Undergoing Definitive Radiation Therapy

      Presenter: Manlu Liu – University of Wisconsin School of Medicine and Public Health

    • 2:45 PM – 4:15 PM ET
      A Prospective Observational Trial on Ablative SBRT for Mediastinal and Hilar Lymphnodes: Preliminary Results

      Presenter: Mauro Loi, MD – Azienda Ospedaliera Universitaria Careggi

    • 2:45 PM – 4:15 PM ET
      Potential Link between Hypoxic Status of Tumors and Surgical Outcomes in NSCLC Patients

      Presenter: Jie Man Low, MB, ChB – Buckinghamshire Healthcare NHS Trust

    • 2:45 PM – 4:15 PM ET
      Helical Tomotherapy Compared to Intensity-Modulated Radiation Therapy in Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients with Limited-Stage Small-Cell Lung Cancer

      Presenter: Shuangqing Lu

    • 2:45 PM – 4:15 PM ET
      Failure Patterns of Postoperative Patients with Positive LNS 2: Possibility of Optimizing Clinical Target Volume

      Presenter: Yifei Lu, MD – Shanghai Chest Hospital, Shanghai Jiao Tong University

    • 2:45 PM – 4:15 PM ET
      Assessing the Safety and Efficacy of a Hypofractionated Regimen in the Treatment of Early-Stage Non-Small Cell Lung Cancer Patients with Central or Ultracentral Tumors

      Presenter: Maryanne Lubas, DO – Fox Chase Cancer Center

    • 2:45 PM – 4:15 PM ET
      Impact of Locoregional Recurrence vs. Distant Metastasis on Overall Survival in Patients with Non-Small Cell Lung Cancer after Surgery: A Secondary Analysis of a Randomized Controlled Trial

      Presenter: Zeliang Ma, MD – Mayo Clinic Rochester

    • 2:45 PM – 4:15 PM ET
      Longitudinal Trends in Patient Portal Use among Patients with Cancer

      Presenter: Nathan Magalit, BA – UC San Diego School of Medicine

    • 2:45 PM – 4:15 PM ET
      Association between Inter-Fraction Tumor Volume Changes and Patient Outcomes from Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer

      Presenter: Wilson Mai, MD, PhD – Stanford University Cancer Center

    • 2:45 PM – 4:15 PM ET
      A Pilot Study to Evaluate Percussive Ventilation Breath Hold to Improve Lung Stereotactic Ablative Radiotherapy (PVB-SABR)

      Presenter: Wilson Mai, MD, PhD – Stanford University Cancer Center

    • 2:45 PM – 4:15 PM ET
      The Impact of the Time of Day of Radiotherapy and Systemic Therapy on Disease Control in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiation and Durvalumab

      Presenter: Matthew McMillan, MD – Memorial Sloan Kettering Cancer Center

    • 2:45 PM – 4:15 PM ET
      Does NLR Remain Prognostic in Sarcopenic Lung and Oesophageal Cancer Patients?

      Presenter: Alan McWilliam, PhD – University of Manchester

    • 2:45 PM – 4:15 PM ET
      Parametric Response Mapping to Predict Pulmonary Toxicity from Thoracic Radiation

      Presenter: Sean Miller, MD – University of Michigan

    • 2:45 PM – 4:15 PM ET
      Cardiac Toxicity in Patients with NSCLC Receiving Radiotherapy or Combined Other Therapies

      Presenter: You Mo

    • 2:45 PM – 4:15 PM ET
      Examining Barriers to Practice and Career Development among Non-Female GYN Radiation Oncologists and Non-Male GU Radiation Oncologists: A Nationwide Survey

      Presenter: Shalini Moningi, MD – Brigham and Women's Hospital/Dana-Farber

    • 2:45 PM – 4:15 PM ET
      Language Disparities in Patient Portal Access and Use among Radiation Oncology Patients Across an Integrated Health Enterprise

      Presenter: Javier Mora, MD – Harvard Radiation Oncology Program

    • 2:45 PM – 4:15 PM ET
      Dosimetric Impact of Online Adaptive Radiotherapy on a Phase II Study of Hypofractionated Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

      Presenter: Ryan Mueller, MD, RT – Barnes Jewish Hospital

    • 2:45 PM – 4:15 PM ET
      Efficacy of Immune-Related Combination Therapy in Peri-Brain Radiotherapy on Non-Sensitive Genetic Mutation-Driven NSCLC with Brain Metastases

      Presenter: Erha Munai

    • 2:45 PM – 4:15 PM ET
      Understanding the Landscape of Radiation Therapy in Alexandria, Egypt: A Comprehensive Study on Physicians, Supporting Staff and Patients Perspectives

      Presenter: Ahmed Nawwar, MD, MPH – Harvard Medical College/Brigham and Women's Hospital/Dana Farbar Cancer Institute

    • 2:45 PM – 4:15 PM ET
      Evaluating Baseline Socioeconomic Factors and Ability for Self-Care in Patients with Head and Neck Cancer: Secondary Analysis of a Prospective Pilot Trial

      Presenter: Nga Nguyen, MD, MD, MPH – Wake Forest Baptist Medical Center

    • 2:45 PM – 4:15 PM ET
      Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer

      Presenter: James Ninia, MD, MS – Yale Therapeutic Radiology

    • 2:45 PM – 4:15 PM ET
      Definitions of Local Control after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer: A Systematic Review of the Literature

      Presenter: Niki Nourmohammadi, DO, MPH – Larkin Community Hospital

    • 2:45 PM – 4:15 PM ET
      Effect of the Time-of-Day of Radiotherapy Administration on Radiation-Induced Lymphocyte Depletion in Lung Cancer

      Presenter: Zuzanna Nowicka, MD – Medical University of Lodz

    • 2:45 PM – 4:15 PM ET
      Real-World Practice Patterns of Immunotherapy, Chemotherapy, and Targeted Therapy with Radiation Therapy in Early-Stage Node-Negative Non-Small Cell Lung Cancer

      Presenter: Patrick Oh, MD – Yale School of Medicine

    • 2:45 PM – 4:15 PM ET
      COPD, Pneumonia and Diabetes: Common Comorbidities Influence Pneumonitis Risk after ChemoRT and Adjuvant Durvalumab in Stage III Non Small Cell Lung Cancer

      Presenter: Timur Mitin, MD, PhD – Oregon Health and Science University

    • 2:45 PM – 4:15 PM ET
      Cost-Utility Analysis of SBRT vs. Surgery for Patients with Stage I Non-Small Cell Lung Cancer in Japan

      Presenter: Hiroshi Onishi, MD, PhD – University of Yamanashi School of Medicine

    • 2:45 PM – 4:15 PM ET
      Comprehensive Assessment of Pneumonitis, Pseudoprogression and Hyperprogression among Inoperable Stage III NSCLC Patients Treated with Trimodal Therapy

      Presenter: Jayson Paragas, MD – McGill University Health Centre

    • 2:45 PM – 4:15 PM ET
      Omission of Prophylactic Cranial Irradiation for Limited Stage Small Cell Lung Cancer

      Presenter: Sean Parker, MD – Cleveland Clinic Health System

    • 2:45 PM – 4:15 PM ET
      An Analysis of the Distribution and Density of Rectal Spacer Implanters for Men Receiving Prostate Radiotherapy across the United States

      Presenter: Sagar Patel, MD – Emory University

    • 2:45 PM – 4:15 PM ET
      Congruence of the Per-Fraction Pet Signal and the Delivered Doses in Biology-Guided Radiotherapy (BgRT)

      Presenter: Daniel Pham, PhD, CMD – Stanford Health Care

    • 2:45 PM – 4:15 PM ET
      A Combined Machine Learning Model for Predicting Pneumonitis of NSCLC Patients Treated with SBRT

      Presenter: Tarun Podder, PhD – SUNY Upstate Medical University

    • 2:45 PM – 4:15 PM ET
      Overall Survival Prediction Utilizing Support Vector Machine with Cluster Partitioning Methodology for NSCLC Patients Treated with SBRT

      Presenter: Tarun Podder, PhD – SUNY Upstate Medical University

    • 2:45 PM – 4:15 PM ET
      Human-Centered Systems Modeling for Mobile Radiation Oncology Implementation

      Presenter: Alex Price, PhD, MS – University Hospitals Cleveland Medical Center

    • 2:45 PM – 4:15 PM ET
      National Survey of Factors Influencing Specialty Selection among Medical Students Interested in Oncology Careers

      Presenter: Krishna Reddy, MD, PhD – University of Kansas Medical Center

    • 2:45 PM – 4:15 PM ET
      Randomized Phase II Trial of Hypofractionated IMRT with 2.5 Gy/Fxn vs. Standard-Fractionated IMRT, Concurrent with Carboplatin/paclitaxel and Followed By Consolidation Durvalumab, for Patients with St

      Presenter: Krishna Reddy, MD, PhD – University of Kansas Medical Center

    • 2:45 PM – 4:15 PM ET
      Does the Implementation of Last Generation Radiation Therapy Equipments Impact in the Interval between the First Clinical Visit to the First Treatment Fraction in a Public Health Scenario?

      Presenter: Jose Regis Neto, MD – Fundacao Assistencial da Paraiba (FAP)

    • 2:45 PM – 4:15 PM ET
      Role of Retreatment with Stereotactic Ablative Body Radiotherapy (SABR) in Oligorecurrent Mesothelioma: A Retrospective Monocentric Study

      Presenter: Alberto Revelant, MD – CRO AVIANO

    • 2:45 PM – 4:15 PM ET
      Assessing Compliance and Diversity in Early Phase Radiation Oncology Clinical Trials in the United States

      Presenter: Atefeh Rezaei, MD – Case Comprehensive Cancer Center, Case Western Reserve University

    • 2:45 PM – 4:15 PM ET
      Proton Radiotherapy for Primary Lung Cancer in Patients with Interstitial Lung Disease

      Presenter: Richard Roden – Mayo Clinic Alix School of Medicine

    • 2:45 PM – 4:15 PM ET
      Self-Reported Financial Toxicity among Rural Cancer Patients Treated with Radiotherapy

      Presenter: Melanie Rose, MD – Dartmouth-Hitchcock Medical Center

    • 2:45 PM – 4:15 PM ET
      Stereotactic Ablative Radiotherapy for Ultra-Central Lung Tumors: Local Control and Toxicity from a Seventeen-Year Single-Institution Experience

      Presenter: Amir Safavi, MD, MSc – Memorial Sloan Kettering Cancer Center

    • 2:45 PM – 4:15 PM ET
      Validation of Spanish-Language Surveys Utilized for the Navigator-Assisted Hypofractionation Program to Aid Hispanic-American Breast Cancer Patients

      Presenter: Abizairie Sánchez-Feliciano, BS – Case Western Reserve University School of Medicine

    • 2:45 PM – 4:15 PM ET
      Visualizing the Radiation Experience for Rural Cancer Patients

      Presenter: Seth Seifert, MA – University of Utah School of Medicine

    • 2:45 PM – 4:15 PM ET
      Global Interobserver Variations of Prescription and Plan Evaluation within Heterogeneous Clinical Target Volume (CTV) Delineations among International Experts in Lung Cancer

      Presenter: Ugur Selek, MD, FASTRO, Prof. – Koc University School of Medicine

    • 2:45 PM – 4:15 PM ET
      Telephone Utilization by Older Adults with Cancer Presenting for Radiation Oncology Consultation

      Presenter: Yasamin Sharifzadeh, MD – Mayo Clinic Rochester

    • 2:45 PM – 4:15 PM ET
      NRG LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell

      Presenter: Charles Simone, MD, FASTRO – New York Proton Center and Memorial Sloan Kettering Cancer Center

    • 2:45 PM – 4:15 PM ET
      Machine Learning Based Predictive Modeling of Pneumonitis in Patients Receiving Radiotherapy and Immunotherapy

      Presenter: Deven Singh, BA – Rutgers Robert Wood Johnson Medical School

    • 2:45 PM – 4:15 PM ET
      A Phase II Randomized Clinical Trial (MC1623) of Concurrent Chemotherapy and Standard (60-66 Gy) vs. High (72 Gy) Dose Proton Beam Therapy (PBT) for Patients with Unresectable, Stage II/III Non-Small

      Presenter: Terence Sio, MD, MS – Mayo Clinic

    • 2:45 PM – 4:15 PM ET
      Survival and Recurrence Rates Following SBRT or Surgery in Medically Operable Stage I NSCLC

      Presenter: Michael Snider, BS – Duke University School of Medicine

    • 2:45 PM – 4:15 PM ET
      Exploring the Demographic Composition of Clinical Research Enrollment in Radiation Oncology

      Presenter: Nichelle Solomon, BS – New York Proton Center

    • 2:45 PM – 4:15 PM ET
      Radiogenomics Models for Predicting Prognosis in Locally Advanced Non-Small Cell Lung Cancer Patients Undergoing Definitive Chemoradiotherapy

      Presenter: Xiaoyu Song, MD – Shandong Cancer Hospital and Institute

    • 2:45 PM – 4:15 PM ET
      Clinical Factors and Major Pathological Response after Neoadjuvant Chemoimmunotherapy in Potentially Resectable Lung Squamous Cell Carcinoma

      Presenter: Yingqiu Song – Liaoning Cancer Hospital

    • 2:45 PM – 4:15 PM ET
      Clinical and Dosimetric Predictors of Cardiotoxicity in Thoracic Radiotherapy for Locally Advanced Lung Cancer

      Presenter: Ana Soto, MD – Hospital de la Santa Creu i Sant Pau

    • 2:45 PM – 4:15 PM ET
      Impact of Limited English Proficiency on Breast Cancer Outcomes

      Presenter: Daphna Spiegel, MD, MS – Beth Israel Deaconess Medical Center

    • 2:45 PM – 4:15 PM ET
      Effects of Target Coverage on Local Recurrence in Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer

      Presenter: Shuou Sudo, MD – Nagoya Proton Therapy Center

    • 2:45 PM – 4:15 PM ET
      Comparison of Perceptions of Barriers to Advancement for Women in Radiation Oncology between Men and Women Physicians

      Presenter: Andrew Tam, MD – City of Hope National Medical Center

    • 2:45 PM – 4:15 PM ET
      The Risk and Survival Significance of Immunotherapy and Targeted Therapy in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

      Presenter: Birhan Alemnew Tamene

    • 2:45 PM – 4:15 PM ET
      Effectiveness and Safety of Definitive Radiation Therapy in Oldest Old Patients (=90 years): A Matched Pair Analysis

      Presenter: Hidekazu Tanaka, MD, PhD – Yamaguchi University Graduate School of Medicine

    • 2:45 PM – 4:15 PM ET
      Optimal Timing of Immunoradiotherapy: Immune Checkpoint Inhibitor before or after Radiation Therapy?

      Presenter: Hidekazu Tanaka, MD, PhD – Yamaguchi University Graduate School of Medicine

    • 2:45 PM – 4:15 PM ET
      Analysis of the lung dose reduction in patients treated by deep-inspiration breath-hold real-time tumor-tracking radiotherapy

      Presenter: Hidekazu Tanaka, MD, PhD – Yamaguchi University Graduate School of Medicine

    • 2:45 PM – 4:15 PM ET
      Upfront Stereotactic Body Radiotherapy to the Residual Primary Lung Lesions after First-Line Systemic Therapy in Polymetastatic Non-Small Cell Lung Cancer

      Presenter: Dan Tao, MD – Chongqing University Cancer Hospital

    • 2:45 PM – 4:15 PM ET
      CRUISER: A Phase 2 Trial of Concurrent durvalumab with Chemoradiation Therapy Followed by durvalumab in Chinese Unresectable Stage III Non-Small Cell Lung Cancer Patients

      Presenter: Feifei Teng, MD, PhD – Shandong Anti-Cancer Association

    • 2:45 PM – 4:15 PM ET
      Noninvasive Radiomic Biomarkers for Predicting Pseudoprogression and Hyperprogression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

      Presenter: Feifei Teng, MD, PhD – Shandong Anti-Cancer Association

    • 2:45 PM – 4:15 PM ET
      CT-Based Radiomics and Genomics Analysis for Survival Prediction in Stage III Unresectable Non-Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy Following with Immunotherapy

      Presenter: Feifei Teng, MD, PhD – Shandong Anti-Cancer Association

    • 2:45 PM – 4:15 PM ET
      A Meta-Analysis of Daily vs. Nonconsecutive Fractionation Schedules for Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

      Presenter: Maximillian Tjauw – University of Oklahoma Health Sciences Center

    • 2:45 PM – 4:15 PM ET
      4DPET/4DCT Image Features to Predict Long-Term Response after Chemo-Radiotherapy for Locally-Advanced Non-Small Cell Lung Cancer

      Presenter: Daniel Tong, MbChB – Princess Margaret Cancer Centre

    • 2:45 PM – 4:15 PM ET
      A First-in-Human Study of the Radiopharmaceutical [225Ac]-FPI-2068 in Patients (pts) with Advanced Solid Tumors

      Presenter: Aditya Juloori, MD – University of Chicago

    • 2:45 PM – 4:15 PM ET
      Application of Radiomic and Dosiomic Analyses to Predict for Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer on the NRG Oncology RTOG 0617 Dataset

      Presenter: Taman Upadhaya, PhD – Cedars-Sinai Medical Center

    • 2:45 PM – 4:15 PM ET
      Medically Inoperable Early-Stage Lung Cancer Patients with Organ Transplants Treated with SBRT Have Impaired Outcomes

      Presenter: Gregory Videtic, MD, FASTRO, CM, FRCPC, FACR – Cleveland Clinic Taussig Cancer Center

    • 2:45 PM – 4:15 PM ET
      Outcomes of Patients with Interstitial Lung Disease and Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy

      Presenter: Samantha Vuong, BS – University of Wisconsin School of Medicine and Public Health

    • 2:45 PM – 4:15 PM ET
      CCL20 Remodeling the Immune Microenvironment via the CD6-Alcam Axis Overcomes NSCLC Immunotherapy Resistance

      Presenter: Weitao Wen, PhD – Shandong Cancer Hospital Affiliated to Shandong First Medical University

    • 2:45 PM – 4:15 PM ET
      Molecular Imaging Research on 18F-FDG PET/CT and Biomarker Analysis Predict the Efficacy of Neoadjuvant Camrelizumab Combined with Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

      Presenter: Kaiyue Wang, MBBS

    • 2:45 PM – 4:15 PM ET
      Incidence and Risk Factors for Pneumonitis Associated with Checkpoint Inhibitors and Chemotherapy in Extensive-Stage Small Cell Lung Cancer

      Presenter: Linlin Wang, MD, PhD – Shandong Cancer Hospital and Institute

    • 2:45 PM – 4:15 PM ET
      Chemoradiotherapy (CRT) Combined with Consolidative Iruplinalkib for ALK/ROS1+ Unresectable Non-Small Cell Lung Cancer (NSCLC): ALK+ Cohort Results from Part 1 of the INNOVATION Study

      Presenter: Linlin Wang, MD, PhD – Shandong Cancer Hospital and Institute

    • 2:45 PM – 4:15 PM ET
      Identification of a Novel Immune-Related Signature to Assess Prognosis and Immunotherapy Efficacy in Lung Squamous Cell Carcinoma

      Presenter: Tianlu Wang, PhD – Liaoning Cancer Hospital

    • 2:45 PM – 4:15 PM ET
      Designing a Question-Based Patient Education System Powered by Generative AI to Narrow the Information Gap for Underserved Populations

      Presenter: Yi Wang, PhD – Massachusetts General Hospital

    • 2:45 PM – 4:15 PM ET
      Small Cell Lung Cancer Patients with Supraclavicular or Cervical Lymph Node Metastasis should be Treated with Limited-Stage Treatment Regimen

      Presenter: Yimeng Wang – Shandong Cancer Hospital and Institute

    • 2:45 PM – 4:15 PM ET
      The Value of Radiotherapy for Patients with Extensive-Stage Small Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

      Presenter: Yunfeng Wang, MD – Shanghai Chest Hospital Shanghai Jiao Tong University

    • 2:45 PM – 4:15 PM ET
      Characterization of Decision Points, Metastatic Trajectories and Outcomes in Advanced NSCLC

      Presenter: Ross Weber, MD, PhD – Memorial Sloan Kettering Cancer Center

    • 2:45 PM – 4:15 PM ET
      Improved Treatment Package Times with Head and Neck Multidisciplinary Clinic Care in Patients with High-Risk Socioeconomic Features

      Presenter: Christopher Wilke, MD, PhD – UPMC Hillman Cancer Center

    • 2:45 PM – 4:15 PM ET
      Development of Evidence-Based Multilingual Patient Education Materials in a Multidisciplinary Rectal Cancer Clinic

      Presenter: Matthew Abrams, MD – Beth Israel Deaconess Medical Center

    • 2:45 PM – 4:15 PM ET
      A Pragmatic Approach to Developing a Lung Nodal Station Atlas as Baseline Data for an Auto-segmentation Algorithm

      Presenter: Harroun Wong, MD – Princess Margaret Cancer Center, University Health Network

    • 2:45 PM – 4:15 PM ET
      Benefit of Thoracic Radiotherapy Following First-Line Chemoimmunotherapy in ES-SCLC: Stratified by Clinical and Therapeutic Characteristics

      Presenter: Jiake Wu – Shandong Cancer Hospital and Institute, Shandong First Medical University

    • 2:45 PM – 4:15 PM ET
      The Molecular Mechanism by Which Statins Overcome Radiotherapy Resistance in Non-Small Cell Lung Cancer

      Presenter: Weitao Wen, PhD – Shandong Cancer Hospital Affiliated to Shandong First Medical University

    • 2:45 PM – 4:15 PM ET
      Impact of Race/Ethnicity on Receiving Post-Mastectomy Reconstruction and Proton Radiation

      Presenter: Amulya Yalamanchili, MD – McGaw Medical Center of Northwestern University

    • 2:45 PM – 4:15 PM ET
      Reducing the Risk of Grade 3 or Greater Radiation Pneumonitis after Radical Radiotherapy to the Lung

      Presenter: Yujie Yan

    • 2:45 PM – 4:15 PM ET
      A Deep Pathomics Model Based on Transformer for the Prediction of Radioimmune-Associated Pneumonitis in Non-Small Cell Lung Cancer

      Presenter: Linlin Yang, MD – Shandong University

    • 2:45 PM – 4:15 PM ET
      Quantitative Evaluation of Accumulated and Planned Dose Deviations in Gated and Non-Gated Lung SBRT Patients

      Presenter: Yaping Xu, PhD – Shanghai Pulmonary Hospital

    • 2:45 PM – 4:15 PM ET
      The Efficacy and Safety of TQB2450 Combined with Anlotinib as Maintenance Therapy for LS-SCLC after Definitive Concurrent or Sequential Chemoradiotherapy: A Prospective Phase Ib Study

      Presenter: Xiaoyan Yin, MBBS – Shandong Cancer Hospital Affiliated to Shandong First Medical University

    • 2:45 PM – 4:15 PM ET
      CT-Based Radiomics Model Predicts Occult Lymph Node Metastasis in Patients with Early-Stage Lung Adenocarcinoma: A Multicenter Study

      Presenter: Xiaoyan Yin, MBBS – Shandong Cancer Hospital Affiliated to Shandong First Medical University

    • 2:45 PM – 4:15 PM ET
      Predicting Micropapillary or Solid Pattern of Early-Stage Lung Adenocarcinoma with CT-Based Radiomics: A Multicenter Study

      Presenter: Xiaoyan Yin, MBBS – Shandong Cancer Hospital Affiliated to Shandong First Medical University

    • 2:45 PM – 4:15 PM ET
      Development and External Validation of Predictive Models for Atrial Fibrillation Following Radiotherapy in Non-Small Cell Lung Cancer Patients

      Presenter: Hong In Yoon, MD, PhD – Yonsei University College of Medicine

    • 2:45 PM – 4:15 PM ET
      Rural Practice Choice Among Radiation Oncology Graduates, 2015 to 2022

      Presenter: Kristin Hsieh, MD – Icahn School of Medicine at Mount Sinai

    • 2:45 PM – 4:15 PM ET
      Stereotactic Body Radiotherapy Plus First-Line EGFR-TKIs for Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis

      Presenter: Ze Yuan, MD

    • 2:45 PM – 4:15 PM ET
      Incidence, Risk Factors and CT Characteristics of Radiation Recall Pneumonitis Induced by COVID-19 Infection in Lung Cancer

      Presenter: Wenhua Yun

    • 2:45 PM – 4:15 PM ET
      Efficacy of Radiotherapy Combined with EGFR-TKI in the Treatment of EGFR/TP53 Co-Mutated NSCLC

      Presenter: Siwei Zeng

    • 2:45 PM – 4:15 PM ET
      Optimized Hippo-Avoidance Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer Treated with First-Line Chemoradiotherapy

      Presenter: Tianyou Zhan, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC

    • 2:45 PM – 4:15 PM ET
      Timing of Once-Daily Thoracic Radiotherapy and Clinical Outcomes in Patients with Limited-Stage Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

      Presenter: Tianyou Zhan, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC

    • 2:45 PM – 4:15 PM ET
      Conditional Survival and Hazard Rates of Patients with LS-SCLC Underwent IMRT in the First-Line Chemoradiotherapy Era: Influence of Prognostics Factors over Time

      Presenter: Tianyou Zhan, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC

    • 2:45 PM – 4:15 PM ET
      Efficacy and Safety of Thoracic Radiotherapy for Extensive-Stage Small-Cell Lung Cancer in the Era of Immunotherapy: A Real-World Study

      Presenter: Chaonan Zhang, MD – National Cancer Center/National Clinical Research Center for Cance

    • 2:45 PM – 4:15 PM ET
      Early Cardio-Oncology Intervention in Thoracic Radiotherapy: Results of the Cardiac Aggressive Risk Mitigation (CARMA) Pilot Study

      Presenter: Samuel Zhang, MD – Cedars-Sinai Medical Center

    • 2:45 PM – 4:15 PM ET
      Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study

      Presenter: Yan Zhang, PhD – Shenzhen Hospital of University of Hong Kong

    • 2:45 PM – 4:15 PM ET
      Radiofrequency Radiation Reshapes Tumor Immune Microenvironment in Pulmonary Metastatic Melanoma By Inducing Active Transformation of Tumor-Infiltrating CD8+ T and NK Cells

      Presenter: Yang Zhang, DSc, PhD

    • 2:45 PM – 4:15 PM ET
      Online Adaptive MR-Guided Fractionated Stereotactic Radiotherapy for Brain Metastases in Patients with Non-Small Cell Lung Cancer (GASTO-1075)

      Presenter: Hui Liu, MD, PhD – Sun Yat-Sen University Cancer Center

    • 2:45 PM – 4:15 PM ET
      Efficacy of Radiotherapy Combined with Atezolizumab or Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer: A PSM-IPTW Cohort Study

      Presenter: Jian-Guo Zhou, MD – Universitatsklinikum Erlangen Universitat Erlangen-Nurnberg

    • 2:45 PM – 4:15 PM ET
      First-Line Tyrosine Kinase Inhibitor with or without Upfront Stereotactic Body Radiotherapy for Residual Primary Lesions in Advanced EGFR-Mutated Non-Small Cell Lung Cancer

      Presenter: We Zhou, MD

    • 2:45 PM – 4:15 PM ET
      Effect of Radiotherapy on Immunotherapy Efficacy for Advanced EGFR Mutant Non-Small Cell Lung Cancers after Osimertinib Resistance

      Presenter: YuanLiang Zhou, MBBS

    • 2:45 PM – 4:15 PM ET
      Real-World Patterns of Cranial Radiation Therapy Among Patients with Brain Metastases from Non-Small Cell Lung Cancer in the Era of CNS-Penetrant Tyrosine Kinase Inhibitors

      Presenter: Lin Zhu, MD, PhD – Harvard Radiation Oncology Program

    • 2:45 PM – 4:15 PM ET
      Disparities in the Efficacy of Different Treatment Modalities for Inoperable Non-Small Cell Lung Cancer in the Immune Era: A Retrospective, Real-World Study

      Presenter: Xue-Ru Zhu, MD, PhD – Shanghai Jiao Tong University

    • 2:45 PM – 4:15 PM ET
      Distribution of Responsibility across the HDR Brachytherapy Team: Results of a Nationwide Survey

      Presenter: Jacqueline Zoberi, PhD – Washington University School of Medicine in St. Louis

    • 2:45 PM – 4:15 PM ET
      Curative-Intent Chemoradiotherapy with Adjuvant Durvalumab plus SBRT to Metastatic Sites in Synchronous Oligometastatic NSCLC

      Presenter: Kyra McComas, MD – Vanderbilt University Medical Center